About Zura Bio

Zura Bio is developing dual-pathway therapies for severe autoimmune and inflammatory disorders, focusing on the efficacy and safety of its lead candidates, tibulizumab, crebankitug, and torudokimab. The company addresses the limitations of existing single-pathway treatments, aiming to improve patient outcomes and quality of life.

```xml <problem> Many autoimmune and inflammatory diseases are inadequately treated by existing therapies that target only a single disease pathway. Patients often require multiple medications to manage their conditions, leading to increased side effects and limited overall efficacy. </problem> <solution> Zura Bio is developing a portfolio of dual-pathway therapies designed to address the limitations of single-target treatments for severe autoimmune and inflammatory disorders. Their investigational drugs, including tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), are being evaluated for their potential to improve patient outcomes by simultaneously modulating key pathways involved in disease pathogenesis. By targeting multiple mechanisms, Zura Bio aims to achieve greater efficacy, reduce the need for combination therapies, and enhance the safety profile of autoimmune and inflammatory disease treatments. The company is currently conducting Phase 2 clinical trials to assess the efficacy and safety of their lead candidate, tibulizumab, in systemic sclerosis and hidradenitis suppurativa. </solution> <features> - Tibulizumab (ZB-106): Investigational monoclonal antibody targeting a specific dual-pathway mechanism relevant in multiple autoimmune diseases; currently in Phase 2 clinical trials. - Crebankitug (ZB-168): Novel therapeutic candidate engineered to modulate distinct, yet complementary, pathways implicated in inflammatory responses. - Torudokimab (ZB-880): Preclinical asset with a unique mechanism of action designed to address unmet needs in specific autoimmune indications. - Dual-pathway approach: Aims to provide more comprehensive disease control compared to single-target therapies. </features> <target_audience> The primary target audience includes patients suffering from severe autoimmune and inflammatory conditions, as well as physicians specializing in rheumatology, dermatology, and gastroenterology seeking more effective treatment options. </target_audience> ```

What does Zura Bio do?

Where is Zura Bio located?

Zura Bio is based in San Diego, United States.

When was Zura Bio founded?

Zura Bio was founded in 2022.

How much funding has Zura Bio raised?

Zura Bio has raised 112500000.

Location

San Diego, United States

Founded

2022

Funding

112500000

Employees

36 employees

Major Investors

Access Biotechnology

Looking for specific startups?

Try our free semantic startup search

Zura Bio

Score: 100/100

AI-Generated Company Overview (experimental) – could contain errors

Executive Summary

zurabio.com 1K+

Crunchbase

Founded 2022 – San Diego, United States

Funding

Estimated Funding

$112.5M+

Major Investors

Access Biotechnology

Team (30+)

Amit Munshi

Sandeep Kulkarni

Chief Executive Officer

Company Description

Problem

Many autoimmune and inflammatory diseases are inadequately treated by existing therapies that target only a single disease pathway. Patients often require multiple medications to manage their conditions, leading to increased side effects and limited overall efficacy.

Solution

Zura Bio is developing a portfolio of dual-pathway therapies designed to address the limitations of single-target treatments for severe autoimmune and inflammatory disorders. Their investigational drugs, including tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880), are being evaluated for their potential to improve patient outcomes by simultaneously modulating key pathways involved in disease pathogenesis. By targeting multiple mechanisms, Zura Bio aims to achieve greater efficacy, reduce the need for combination therapies, and enhance the safety profile of autoimmune and inflammatory disease treatments. The company is currently conducting Phase 2 clinical trials to assess the efficacy and safety of their lead candidate, tibulizumab, in systemic sclerosis and hidradenitis suppurativa.

Features

Tibulizumab (ZB-106): Investigational monoclonal antibody targeting a specific dual-pathway mechanism relevant in multiple autoimmune diseases; currently in Phase 2 clinical trials.

Crebankitug (ZB-168): Novel therapeutic candidate engineered to modulate distinct, yet complementary, pathways implicated in inflammatory responses.

Torudokimab (ZB-880): Preclinical asset with a unique mechanism of action designed to address unmet needs in specific autoimmune indications.

Dual-pathway approach: Aims to provide more comprehensive disease control compared to single-target therapies.

Target Audience

The primary target audience includes patients suffering from severe autoimmune and inflammatory conditions, as well as physicians specializing in rheumatology, dermatology, and gastroenterology seeking more effective treatment options.